| Drug Name |
Pamidronic acid |
| Drug ID |
BADD_D01662 |
| Description |
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977.[A203267] The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic acid], [minodronic acid], and [risedronic acid] are becoming more popular.[A203111]
Pamidronic acid was granted FDA approval on 31 October 1991.[L13835] |
| Indications and Usage |
Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.[L13838] |
| Marketing Status |
approved |
| ATC Code |
M05BA03 |
| DrugBank ID |
DB00282
|
| KEGG ID |
D07281
|
| MeSH ID |
D000077268
|
| PubChem ID |
4674
|
| TTD Drug ID |
D0BF8G
|
| NDC Product Code |
53104-7611; 50711-0003 |
| UNII |
OYY3447OMC
|
| Synonyms |
Pamidronate | Amino-1-hydroxypropane-1,1-diphosphonate | Amino 1 hydroxypropane 1,1 diphosphonate | AHPrBP | Aminopropanehydroxydiphosphonate | Amidronate | (3-Amino-1-hydroxypropylidene)-1,1-biphosphonate | Aminohydroxypropylidene Diphosphonate | 1-Hydroxy-3-aminopropane-1,1-diphosphonic acid | 1 Hydroxy 3 aminopropane 1,1 diphosphonic acid | Pamidronic Acid | Pamidronate Monosodium | Pamidronate Calcium | Pamidronate Disodium | Aredia |
